Literature DB >> 10407016

kappa-Opioid tolerance and dependence in cultures of dopaminergic midbrain neurons.

F C Dalman1, K L O'Malley.   

Abstract

Repeated cocaine exposure upregulates kappa opioids and their receptors in the mesocorticolimbic system; the ensuing kappa-mediated dysphoria appears to contribute to addiction and withdrawal. As a potential rehabilitation strategy to reverse cocaine-induced kappa sensitization, the present study used tritiated dopamine release assays to examine the induction of kappa-opioid tolerance in cultured mesencephalic neurons. Administration of the kappa agonist U69,593 inhibited tetrodotoxin-sensitive, spontaneous (EC(50) = 1.5 nM), and potassium-stimulated (EC(50) = 10 nM) release. These effects were blocked by pertussis toxin and by the kappa antagonist nor-binaltorphimine. The 2 d agonist exposure (1 microM) caused a shift in the U69,593 dose-response curve that was greater in the potassium-stimulated paradigm (140-fold) than in the spontaneous release assay (sixfold). These results were attributable to the attenuation of kappa-receptor signaling mechanisms and to dependence. In the stimulated release assay, attenuation of kappa signaling caused by 4 hr of U69,593 exposure recovered with a half-life of 1.1 hr, whereas attenuation after 144 hr of exposure recovered slowly (t(1/2) = 20 hr). In the spontaneous release assay, attenuation of kappa-opioid signaling occurred slowly (t(1/2) = 22 hr), and resensitization after a 144 hr exposure was rapid (t(1/2) < 1 hr). kappa-Opioid dependence was observed after 144 hr of U69,593 exposure. Thus multiple mechanisms of adaptation to kappa-opioid exposure occur in mesocorticolimbic neurons. These data support the idea that the administration of kappa opioids might facilitate drug rehabilitation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10407016      PMCID: PMC6783098     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  43 in total

1.  Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway.

Authors:  R Spanagel; A Herz; T S Shippenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

2.  Regulation of cocaine reward by CREB.

Authors:  W A Carlezon; J Thome; V G Olson; S B Lane-Ladd; E S Brodkin; N Hiroi; R S Duman; R L Neve; E J Nestler
Journal:  Science       Date:  1998-12-18       Impact factor: 47.728

3.  Effects of chronic U-50,488H treatment on the isolated right atrium of the rat.

Authors:  M V Milanés; J V Rabadan; M L Laorden
Journal:  Neuropeptides       Date:  1997-10       Impact factor: 3.286

4.  Kappa2 opioid receptors in limbic areas of the human brain are upregulated by cocaine in fatal overdose victims.

Authors:  J K Staley; R B Rothman; K C Rice; J Partilla; D C Mash
Journal:  J Neurosci       Date:  1997-11-01       Impact factor: 6.167

5.  Effect of chronic administration of U-50,488H on tolerance to its pharmacological actions and on multiple opioid receptors in rat brain regions and spinal cord.

Authors:  H N Bhargava; A Gulati; P Ramarao
Journal:  J Pharmacol Exp Ther       Date:  1989-10       Impact factor: 4.030

6.  'Binge' cocaine administration induces a sustained increase of prodynorphin mRNA in rat caudate-putamen.

Authors:  R Spangler; E M Unterwald; M J Kreek
Journal:  Brain Res Mol Brain Res       Date:  1993-09

7.  The kappa-opioid receptor agonist U-69593 attenuates cocaine-induced behavioral sensitization in the rat.

Authors:  C A Heidbreder; S R Goldberg; T S Shippenberg
Journal:  Brain Res       Date:  1993-07-09       Impact factor: 3.252

8.  Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists.

Authors:  P S Portoghese; A W Lipkowski; A E Takemori
Journal:  Life Sci       Date:  1987-03-30       Impact factor: 5.037

9.  Effects of kappa opioid agonists on cocaine- and food-maintained responding by rhesus monkeys.

Authors:  N K Mello; S S Negus
Journal:  J Pharmacol Exp Ther       Date:  1998-08       Impact factor: 4.030

10.  Effects of cocaine on extrapyramidal and limbic dynorphin systems.

Authors:  P L Smiley; M Johnson; L Bush; J W Gibb; G R Hanson
Journal:  J Pharmacol Exp Ther       Date:  1990-06       Impact factor: 4.030

View more
  6 in total

1.  Kappa opioid inhibition of somatodendritic dopamine inhibitory postsynaptic currents.

Authors:  Christopher P Ford; Michael J Beckstead; John T Williams
Journal:  J Neurophysiol       Date:  2006-11-22       Impact factor: 2.714

2.  Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location.

Authors:  Christopher P Ford; Gregory P Mark; John T Williams
Journal:  J Neurosci       Date:  2006-03-08       Impact factor: 6.167

Review 3.  Role of kappa-opioid receptors in stress and anxiety-related behavior.

Authors:  Ashlee Van't Veer; William A Carlezon
Journal:  Psychopharmacology (Berl)       Date:  2013-07-09       Impact factor: 4.530

Review 4.  Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence.

Authors:  Brendan M Walker; Glenn R Valdez; Jay P McLaughlin; Georgy Bakalkin
Journal:  Alcohol       Date:  2012-03-27       Impact factor: 2.405

Review 5.  Traumatic Stress-Induced Vulnerability to Addiction: Critical Role of the Dynorphin/Kappa Opioid Receptor System.

Authors:  Claire Leconte; Raymond Mongeau; Florence Noble
Journal:  Front Pharmacol       Date:  2022-04-27       Impact factor: 5.988

6.  Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism.

Authors:  Bronwyn Kivell; Zeljko Uzelac; Santhanalakshmi Sundaramurthy; Jeyaganesh Rajamanickam; Amy Ewald; Vladimir Chefer; Vanaja Jaligam; Elizabeth Bolan; Bridget Simonson; Balasubramaniam Annamalai; Padmanabhan Mannangatti; Thomas E Prisinzano; Ivone Gomes; Lakshmi A Devi; Lankupalle D Jayanthi; Harald H Sitte; Sammanda Ramamoorthy; Toni S Shippenberg
Journal:  Neuropharmacology       Date:  2014-08-10       Impact factor: 5.250

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.